These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32289294)

  • 1. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; MacLaren RE; Downes SM; Fauser S; Boon CJF; Hoyng CB
    Am J Ophthalmol; 2020 Aug; 216():80-89. PubMed ID: 32289294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
    van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
    van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
    Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4.
    van Rijssen TJ; Hahn LC; van Dijk EHC; Tsonaka R; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Retina; 2021 Oct; 41(10):2122-2131. PubMed ID: 34543244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.
    Breukink MB; Downes SM; Querques G; van Dijk EHC; den Hollander AI; Blanco-Garavito R; Keunen JEE; Souied EH; MacLaren RE; Hoyng CB; Fauser S; Boon CJF
    Trials; 2015 Sep; 16():419. PubMed ID: 26390920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
    Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Scholz P; Altay L; Fauser S
    Eye (Lond); 2016 Oct; 30(10):1371-1377. PubMed ID: 27391938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
    Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
    Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
    Breukink MB; Mohabati D; van Dijk EH; den Hollander AI; de Jong EK; Dijkman G; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and anatomical results of subthreshold micropulse laser as rescue treatment for central serous chorioretinopathy after verteporfin shortage.
    Oribio-Quinto C; Alarcón-Garcia AD; Enriquez-Fuentes J; Burgos-Blasco B; Fernandez-Vigo JI
    Photodiagnosis Photodyn Ther; 2024 Oct; 49():104295. PubMed ID: 39067672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):659-668. PubMed ID: 36202933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.